Zogenix (ZGNX) Earning Somewhat Favorable News Coverage, Report Finds
News articles about Zogenix (NASDAQ:ZGNX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zogenix earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0295636000753 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Commit To Purchase Zogenix At $23, Earn 19.6% Using Options (nasdaq.com)
- BidaskClub Upgrades Zogenix (ZGNX) to “Buy” (americanbankingnews.com)
- Investors Sizing Up Zogenix Inc (ZGNX) As Shares Move -0.20 – Clawson News (clawsonnews.com)
- Way to read Technical data on Zogenix, Inc. (ZGNX) – Wall Street Morning (wallstreetmorning.com)
- Ganaxalone Faces Stiff Competition from Other Drugs under Development (finance.yahoo.com)
A number of brokerages recently commented on ZGNX. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research report on Friday. Mizuho restated a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research report on Thursday, December 7th. JMP Securities began coverage on Zogenix in a research report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price target on the stock. Leerink Swann restated an “outperform” rating and issued a $50.00 price target (up previously from $20.00) on shares of Zogenix in a research report on Monday, October 2nd. Finally, ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $42.67.
Zogenix (ZGNX) opened at $40.05 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.71. Zogenix has a 12-month low of $7.70 and a 12-month high of $43.35. The company has a market capitalization of $1,330.00, a price-to-earnings ratio of -9.12 and a beta of 2.01.
In other Zogenix news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The shares were purchased at an average price of $37.50 per share, for a total transaction of $11,250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Bradley S. Galer bought 1,346 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was acquired at an average price of $36.59 per share, for a total transaction of $49,250.14. The disclosure for this purchase can be found here. Insiders own 5.00% of the company’s stock.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with Analyst Ratings Network's FREE daily email newsletter.